IMMUNOVANT, INC. (IMVT) Free cash flow 2019–2026
IMMUNOVANT, INC. (IMVT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$407.3MFY2026 · since FY2019: -$28.6M → -$407.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$407.3M | -8.1% |
| FY2025 | -$376.6M | -75.5% |
| FY2024 | -$214.6M | -13.9% |
| FY2023 | -$188.4M | -77.1% |
| FY2022 | -$106.4M | -27.3% |
| FY2021 | -$83.5M | -56.5% |
| FY2020 | -$53.4M | -86.7% |
| FY2019 | -$28.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice